I3 Nirf
Boston, US · 1 known investors
Find your way into I3 Nirf
i3 develops a hybrid intravascular imaging catheter combining near-infrared fluorescence (NIRF) and ultrasound (IVUS) sensors to provide real-time molecular and structural imaging during coronary interventions. The system enables detection of arterial injury and complications in cardiac catheterization procedures.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does I3 Nirf do?
- i3 develops a hybrid intravascular imaging catheter combining near-infrared fluorescence (NIRF) and ultrasound (IVUS) sensors to provide real-time molecular and structural imaging during coronary interventions. The system enables detection of arterial injury and complications in cardiac catheterization procedures.
- Who are I3 Nirf's investors?
- I3 Nirf's investors include Broadview Ventures.
- Where is I3 Nirf headquartered?
- I3 Nirf is headquartered in Boston, US.